SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Zuardi, A.W.
Right arrow Articles by Guimarães, F.S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Zuardi, A.W.
Right arrow Articles by Guimarães, F.S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Effects of ipsapirone and cannabidiol on human experimental anxiety

A.W. Zuardi

Laboratory of Psychobiology, FFCLRP, Campus USP, Ribeirao Preto, SP 14049, Brazil

R.A. Cosme

Laboratory of Psychobiology, FFCLRP, Campus USP, Ribeirao Preto, SP 14049, Brazil

F.G. Graeff

Laboratory of Psychobiology, FFCLRP, Campus USP, Ribeirao Preto, SP 14049, Brazil

F.S. Guimarães

Department of Neuropsychiatry and Pharmacology, Faculty of Medicine

The effects of ipsapirone and cannabidiol (CBD) on healthy volunteers submitted to a simulated public speaking (SPS) test were compared with those of the anxiolytic benzodiazepine diazepam and placebo. Four independent groups of 10 subjects received, under a double-blind design, placebo or one of the following drugs: CBD (300 mg), diazepam (10 mg) or ipsapirone (5 mg). Subjective anxiety was evaluated through the Visual Analogue Mood Scale (VAMS) and the State-trait Anxiety Inventory (STAI). The VAMS anxiety factor showed that ipsapirone attenuated SPS-induced anxiety while CBD decreased anxiety after the SPS test. Diazepam, on the other hand, was anxiolytic before and after the SPS test, but had no effect on the increase in anxiety induced by the speech test. Only ipsapirone attenuated the increase in systolic blood pressure induced by the test. Significant sedative effects were only observed with diazepam. The results suggest that ipsapirone and CBD have anxiolytic properties in human volunteers submitted to a stressful situation.

Key Words: cannabidiol • diazepam • ipsapirone • anxiety • public speaking

Journal of Psychopharmacology, Vol. 7, No. 1 suppl, 82-88 (1993)
DOI: 10.1177/026988119300700112


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Arch Gen PsychiatryHome page
P. Fusar-Poli, J. A. Crippa, S. Bhattacharyya, S. J. Borgwardt, P. Allen, R. Martin-Santos, M. Seal, S. A. Surguladze, C. O'Carrol, Z. Atakan, et al.
Distinct Effects of {Delta}9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing
Arch Gen Psychiatry, January 1, 2009; 66(1): 95 - 105.
[Abstract] [Full Text] [PDF]



Advertisement